CoChat
Sign Up
Cited by 62Systemic Lupus Erythematosus ResearchVasculitis and related conditionsSystemic Sclerosis and Related Diseases

Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation

Open access
Martirosyan, Anush, Aminov, Rustam, Manukyan, Gayane·2019·Frontiers in Immunology
DOI 10.3389/fimmu.2019.01609PMC PMC6635959
Open this paper in CoChat — free accountOpen PDF

Abstract

Antiphospholipid antibodies (aPLs) comprise a diverse family of autoantibodies targeted against proteins with the affinity toward negatively charged phospholipids or protein-phospholipid complexes. Their clinical significance, including prothrombotic potential of anti-cardiolipin antibodies (aCLs), anti-β2-glycoprotein I antibodies (aβ2-GPIs), and lupus anti-coagulant (LA), is well-established. However, the ontogeny of these pathogenic aPLs remains less clear. While transient appearance of aPLs could be induced by various environmental factors, in genetically predisposed individuals these factors may eventually lead to the development of the antiphospholipid syndrome (APS). Since the first description of APS, it has been found that a wide variety of microbial and viral agents influence aPLs production and contribute to clinical manifestations of APS. Many theories attempted to explain the pathogenic potential of different environmental factors as well as a phenomenon termed molecular mimicry between β2-GPI molecule and infection-relevant structures. In this review, we summarize and critically assess the pathogenic and non-pathogenic formation of aPLs and its contribution to the development of APS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.01609

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several drugs (antibiotics, antiarrhythmics, chlorpromazine) and vaccines (hepatitis B) can occasionally be associated with LA positivity.

    “Furthermore, several drugs (antibiotics, antiarrhythmics, chlorpromazine) and vaccines (hepatitis B) can occasionally be associated with a LA positivity [24].”

    From Lupus Anticoagulant Detection under the Magnifying Glass (2023) · cites this paper as [24]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 158

  1. [1]Schreiber K Sciascia S de Groot PG Devreese K Jacobsen S Ruiz-Irastorza G Antiphospholipid syndrome. Nat Rev Dis Primers. (2018) 11: 17103 10.1038/nrdp.2017.103 29321641 · DOI
  2. [3]Willis R Pierangeli SS. Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights. (2011) 2: 35– 52. 10.1007/s13317-011-0017-9 26000118 PMC4389016 · DOI
  3. [4]von Landenberg P Doring Y Modrow S Lackner KJ. Are antiphospholipid antibodies an essential requirement for an effective immune response to infections? Ann N Y Acad Sci. (2007) 1108: 578– 83. 10.1196/annals.1422.060 17894022 · DOI
  4. [5]Salmon JE de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. (2008) 17: 405– 11. 10.1177/0961203308090025 18490417 PMC2693020 · DOI
  5. [6]Pericleous C Ruiz-Limón P Romay-Penabad Z Marín AC Garza-Garcia A Murfitt L. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology. (2015) 54: 722– 7. 10.1093/rheumatology/keu360 25273993 PMC4372675 · DOI
  6. [7]Giannakopoulos B Passam F Rahgozar S Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. (2007) 109: 422– 30. 10.1182/blood-2006-04-001206 16985176 · DOI
  7. [8]Nakanishi T Suzuki N Kuragano T Nagasawa Y Hasuike Y. Current topics in therapeutic plasmapheresis. Clin Exp Nephrol. (2014) 18: 41– 9. 10.1007/s10157-013-0838-0 23887747 · DOI
  8. [9]Martirosyan A Petrek M Kishore A Manukyan G. The immunomodulatory effects of therapeutic plasma exchange on monocytes in Antiphospholipid syndrome. Exp Ther Med. (2016) 12: 1189– 95. 10.3892/etm.2016.3441 27446342 PMC4950391 · DOI
  9. [10]McNally T Purdy G Mackie IJ Machin SJ Isenberg DA The use of an anti-beta2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol. (1995) 91: 471– 3. 10.1111/j.1365-2141.1995.tb05324.x 8547096 · DOI
  10. [11]Canoso RT Zon LI Groopman JE. Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol. (1987) 65: 495– 8. 10.1111/j.1365-2141.1987.tb04157.x 3580308 · DOI
  11. [12]Asherson RA Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. (2003) 62: 388– 93. 10.1136/ard.62.5.388 12695147 PMC1754545 · DOI
  12. [13]Sene D Piette JC Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmune Rev. (2008) 7: 272– 7. 10.1016/j.autrev.2007.10.001 18295729 · DOI
  13. [14]Galrão L Brites C Atta ML Atta A Lima I Gonzalez F. Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol. (2007) 26: 1825– 30. 10.1007/s10067-007-0581-6 17332976 · DOI
  14. [15]Uthman IW Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. (2002) 31: 256– 63. 10.1053/sarh.2002.28303 11836658 · DOI
  15. [16]Guglielmone H Vitozzi S Elbarcha O Fernandez E. Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Ann Rheum Dis. (2001) 60: 500– 4. 10.1136/ard.60.5.500 11302873 PMC1753647 · DOI
  16. [17]Gharavi AE Sammaritano LR Wen J Miyawaki N Morse JH Zarrabi MH. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. J Rheumatol. (1994) 21: 94– 9. 8151598
  17. [18]Petrovas C Vlachoyiannopoulos PG Kordossis T Moutsopoulos HM. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun. (1999) 13: 347– 55. 10.1006/jaut.1999.0324 10550222 · DOI
  18. [19]Bibas M Biava G Antinori A. HIV-associated venous thromboembolism. Mediterr J Hematol Infect Dis. (2011) 3: e2011030. 10.4084/mjhid.2011.030 21869916 PMC3152452 · DOI
  19. [20]Giordano P Galli M Del Vecchio GC Altomare M Norbis F. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia. Br J Haematol. (1998) 102: 903– 6. 10.1046/j.1365-2141.1998.00853.x 9734637 · DOI
  20. [21]Ramos-Casals M Cervera R Lagrutta M Medina F García-Carrasco M de la Red G. Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Clin Infect Dis. (2004) 38: 1009– 16. 10.1086/382537 15034835 · DOI
  21. [22]Elefsiniotis IS Diamantis ID Dourakis SP Kafiri G Pantazis K Mavrogiannis C. Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis. Eur J Gastroenterol Hepatol. (2003) 15: 721– 6. 10.1097/01.meg.0000059140.68845.74 12811301 · DOI
  22. [23]Kerr JR. The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. J Clin Pathol. (2016) 69: 279– 91. 10.1136/jclinpath-2015-203455 26644521 · DOI
  23. [24]von Landenberg P Lehmann HW Knöll A Dorsch S Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. (2003) 48: 1939– 47. 10.1002/art.11038 12847688 · DOI
  24. [25]Loizou S Cazabon JK Walport MJ Tait D So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. (1997) 40: 103– 8. 10.1002/art.1780400115 9008606 · DOI
  25. [26]Asano Y Sarukawa M Idezuki T Harada S Kaji K Nakasu I. Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection. Clin Rheumatol. (2006) 25: 585– 7. 10.1007/s10067-005-0032-1 16421644 · DOI
  26. [27]Kranidiotis G Efstratiadis E Kapsalakis G Loizos G Bilis A Melidonis A. Splenic infarcts as a rare manifestation of parvovirus B19 infection. ID Cases. (2016) 4: 62– 4. 10.1016/j.idcr.2016.04.003 27213135 PMC4865634 · DOI
  27. [28]Abdel-Wahab N Lopez-Olivo MA Pinto-Patarroyo GP Suarez-Almazor ME. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. (2016) 25: 1520– 31. 10.1177/0961203316640912 27060064 PMC7508159 · DOI
  28. [29]Williams MV Cox B Ariza ME. Herpesviruses dUTPases: a new family of Pathogen-Associated Molecular Pattern (PAMP) proteins with implications for human disease. Pathogens. (2016) 6: 2. 10.3390/pathogens6010002 28036046 PMC5371890 · DOI
  29. [30]De Carolis S Tabacco S Rizzo F Perrone G Garufi C Botta A. Association between false-positive TORCH and antiphospholipid antibodies in healthy pregnant women. Lupus. (2018). 27: 841– 6. 10.1177/0961203317741564 29157179 · DOI
  30. [31]Justo D Finn T Atzmony L Guy N Steinvil A. Thrombosis associated with acute cytomegalovirus infection: a meta-analysis. Eur J Intern Med. (2011) 22: 195– 9. 10.1016/j.ejim.2010.11.006 21402253 · DOI
  31. [32]Rahbar A Söderberg-Nauclér C. Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. J Virol. (2005) 79: 2211– 20. 10.1128/JVI.79.4.2211-2220.2005 15681423 PMC546536 · DOI
  32. [33]Squizzato A Gerdes VE Büller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost. (2005) 93: 403– 10. 10.1160/TH04-08-0523 15735787 · DOI
  33. [34]Josephson C Nuss R Jacobson L Hacker MR Murphy J Weinberg A. The varicella-autoantibody syndrome. Pediatr Res. (2001) 50: 345– 52. 10.1203/00006450-200109000-00009 11518821 · DOI
  34. [35]Viseux V Darnige L Carmi E Chaby G Poulain JF Cevallos R. Pulmonary embolism and transitory anti-beta2-GPI antibodies in an adult with chicken pox. Lupus. (2000) 9: 558– 60. 10.1177/096120330000900716 11035426 · DOI
  35. [36]Losurdo G Giacchino R Castagnola E Gattorno M Costabel S Rossi A. Cerebrovascular disease and varicella in children. Brain Dev. (2006) 28: 366– 70. 10.1016/j.braindev.2005.11.002 16376509 · DOI
  36. [37]Frontino G Passoni A Piscopo MA Grechi E Cammarata B Pozzobon G. Bilateral cavo-ilio-femoral thrombosis in an adolescent with transient anti-phospholipid antibodies and factor V heterozygous mutation: a case report. Cases J. (2009) 2: 6830. 10.4076/1757-1626-2-6830 19918549 PMC2769319 · DOI
  37. [38]Zandman-Goddard G Berkun Y Barzilai O Boaz M Blank M Ram M. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci. (2009) 1173: 658– 63. 10.1111/j.1749-6632.2009.04754.x 19758212 · DOI
  38. [39]Ogawa J Koike R Sugihara T Hagiyama H Nishio J Kohsaka H. [An autopsied case of chronic active Epstein-Barr virus infection complicated in systemic lupus erythematosus and antiphospholipid antibody syndrome]. Nihon Rinsho Meneki Gakkai Kaishi. (2002) 25: 458– 65. 10.2177/jsci.25.458 12599514 · DOI
  39. [40]Delbos V Abgueguen P Chennebault JM Fanello S Pichard E. Acute cytomegalovirus infection and venous thrombosis: role of antiphospholipid antibodies. J Infect. (2008) 54: e47– 50. 10.1016/j.jinf.2006.03.031 16701900 · DOI
  40. [41]Kratz C Mauz-Körholz C Kruck H Körholz D Göbel U. Detection of antiphospholipid antibodies in children and adolescents. Pediatr Hematol Oncol. (1998) 15: 325– 32. 10.3109/08880019809014016 9658433 · DOI
  41. [42]Shimizu T Ishiguro A Takayanagi T Matsui T Tonegawa N Maekawa T. [A case of lupus anticoagulant hypoprothrombinemia syndrome following adenovirus gastroenteritis and mycoplasma pneumonia]. Nihon Rinsho Meneki Gakkai Kaishi. (2014) 37: 55– 60. 10.2177/jsci.37.55 24598069 · DOI
  42. [43]Mazzon M Mercer J. Lipid interactions during virus entry and infection. Cell Microbiol. (2014) 16: 1493– 502. 10.1111/cmi.12340 25131438 PMC4265854 · DOI
  43. [44]Lorizate M Sachsenheimer T Glass B Habermann A Gerl MJ Krausslich HG. Comparative lipidomics analysis of HIV-1 particles and their producer cell membrane in different cell lines. Cell Microbiol. (2013) 15: 292– 304. 10.1111/cmi.12101 23279151 · DOI
  44. [46]de Armas-Rillo L Valera MS Marrero-Hernández S Valenzuela-Fernández A Membrane dynamics associated with viral infection. Rev Med Virol. (2016) 26: 146– 60. 10.1002/rmv.1872 26817660 PMC5066672 · DOI
  45. [47]Haynes BF Fleming J St Clair EW Katinger H Stiegler G Kunert R. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. (2005) 308: 1906– 8. 10.1126/science.1111781 15860590 · DOI
  46. [48]Martinez V Diemert MC Braibant M Potard V Charuel JL Barin F. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis. (2009) 48: 123– 32. 10.1086/595013 19035778 · DOI
  47. [49]Diaz JS Octavio JG Fernandez-Guerrero ML. Antiphospholipid syndrome and acute HIV infection. Emerg Infect Dis. (2010) 16: 360– 1. 10.3201/eid1602.090728 20113589 PMC2958003 · DOI
  48. [50]Martirosyan A Petrek M Navratilova Z Blbulyan A Boyajyan A Manukyan G. Differential regulation of proinflammatory mediators following LPS- and ATP-induced activation of monocytes from patients with antiphospholipid syndrome. Biomed Res Int. (2015) 2015: 292851. 10.1155/2015/292851 25785264 PMC4345072 · DOI
  49. [51]Arleevskaya MI Manukyan G Inoue R Aminov R. Editorial: microbial and environmental factors in autoimmune and inflammatory diseases. Front Immunol. (2017) 8: 243. 10.3389/fimmu.2017.00243 28321226 PMC5337519 · DOI
  50. [52]Cervera R Asherson RA Acevedo ML Gómez-Puerta JA Espinosa G De La Red G. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis. (2004) 63: 1312– 7. 10.1136/ard.2003.014175 15361392 PMC1754783 · DOI
  51. [53]Snowden N Wilson PB Longson M Pumphrey RS. Antiphospholipid antibodies and Mycoplasma pneumoniae infection. Postgrad Med J. (1990) 66: 356– 62. 10.1136/pgmj.66.775.356 2371184 PMC2426843 · DOI
  52. [54]Ardiles L Ramirez P Moya P Caorsi I Mezzano S. Anticardiolipin antibodies in acute poststreptococcal glomerulonephritis and streptococcal impetigo. Nephron. (1999) 83: 47– 52. 10.1159/000045472 10461035 · DOI
  53. [55]Espinosa G Santos E Cervera R Piette JC de la Red G Gil V. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine. (2003) 82: 106– 18. 10.1097/00005792-200303000-00005 12640187 · DOI
  54. [56]Bakshi M Khemani C Vishwanathan V Anand RK Khubchandani RP. Mycoplasma pneumonia with antiphospholipid antibodies and a cardiac thrombus. Lupus. (2006) 15: 105– 6. 10.1191/0961203306lu2258cr 16539282 · DOI
  55. [57]Graw-Panzer KD Verma S Rao S Miller ST Lee H. Venous thrombosis and pulmonary embolism in a child with pneumonia due to Mycoplasma pneumoniae. J Natl Med Assoc. (2009) 101: 956– 8. 10.1016/S0027-9684(15)31045-2 19806855 · DOI
  56. [58]Witmer CM Steenhoff AP Shah SS Raffini LJ. Mycoplasma pneumoniae, splenic infarct, and transient antiphospholipid antibodies: a new association? Pediatrics. (2007) 119: e292– 5. 10.1542/peds.2006-1340 17178923 · DOI
  57. [59]Harada M Nishi Y Tamura S Iba Y Abe K Yanbe Y. [Infective endocarditis with a huge mitral vegetation related to atopic dermatitis and high serum level of infection-related antiphospholipid antibody: a case report]. J Cardiol. (2003) 42: 135– 40. 14526663
  58. [60]Goldenberg NA Knapp-Clevenger R Hays T Manco-Johnson MJ. Lemierre's and Lemierre's-like syndromes in children: survival and thromboembolic outcomes. Pediatrics. (2005) 116: e543– 8. 10.1542/peds.2005-0433 16147971 · DOI
  59. [61]Johannesen KM Bodtger U. Lemierre's syndrome: current perspectives on diagnosis and management. Infect Drug Resist. (2016) 9: 221– 7. 10.2147/IDR.S95050 27695351 PMC5028102 · DOI
  60. [62]Forastiero RR Martinuzzo ME de Larrañaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus. (2005) 14: 129– 36. 10.1191/0961203305lu2048oa 15751817 · DOI
  61. [63]Avcin T Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. (2007) 9: 212– 8. 10.1007/s11926-007-0034-x 17531174 · DOI
  62. [64]Fiallo P Travaglino C Nunzi E Cardo PP. Beta 2-Glycoprotein I-dependence of anticardiolipin antibodies in multibacillary leprosy patients. Lepr Rev. (1998) 69: 376– 81. 10.5935/0305-7518.19980038 9927810 · DOI
  63. [65]de Larrañaga GF Forastiero RR Martinuzzo ME Carreras LO Tsariktsian G Sturno MM. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. (2000) 9: 594– 600. 10.1191/096120300678828712 11035434 · DOI
  64. [66]Levy RA de Meis E Pierangeli S An adapted ELISA method for differentiating pathogenic from non-pathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay. Thromb Res. (2004) 114: 573– 7. 10.1016/j.thromres.2004.06.032 15507293 · DOI
  65. [67]Ordoñez C Savage HP Tarajia M Rivera R Weeks-Galindo C Sambrano D Both B-1a and B-1b cells exposed to Mycobacterium tuberculosis lipids differentiate into IgM antibody-secreting cells. Immunology. (2018) 154: 613– 23. 10.1111/imm.12909 PMC6050208 29455451 · DOI
  66. [68]Adebajo AO Charles P Maini RN Hazleman BL. Autoantibodies in malaria, tuberculosis and hepatitis B in a west African population. Clin Exp Immunol. (1993) 92: 73– 6. 10.1111/j.1365-2249.1993.tb05950.x 8467567 PMC1554859 · DOI
  67. [69]Elkayam O Caspi D Lidgi M Segal R. Auto-antibody profiles in patients with active pulmonary tuberculosis. Int J Tuberc Lung Dis. (2007) 11: 306– 10. 17352097
  68. [70]Shen CY Hsieh SC Yu CL Wang JY Lee LN Yu CJ Autoantibody prevalence in active tuberculosis: reactive or pathognomonic? BMJ Open. (2013) 26: 7 10.1136/bmjopen-2013-002665 PMC3731725 23892369 · DOI
  69. [71]Elkayam O Bendayan D Segal R Shapira Y Gilburd B Reuter S. The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis. Rheumatol Int. (2013) 33: 949– 53. 10.1007/s00296-012-2487-0 23011089 · DOI
  70. [72]Goodridge A Cueva C Lahiff M Muzanye G Johnson JL Nahid P. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. Tuberculosis. 92: 243– 7. 10.1016/j.tube.2012.02.004 22406155 PMC4408545 · DOI
  71. [73]Backert S Neddermann M Maubach G Naumann M Pathogenesis of Helicobacter pylori infection. Helicobacter Suppl. (2016) 1: 19– 25. 10.1111/hel.12335 27531534 · DOI
  72. [74]Smyk DS Koutsoumpas AL Mytilinaiou MG Rigopoulou EI Sakkas LI Bogdanos DP Helicobacter pylori and autoimmune disease: cause or bystander. World J Gastroenterol. (2014) 20: 613– 29. 10.3748/wjg.v20.i3.613 24574735 PMC3921471 · DOI
  73. [75]Ram M Barzilai O Shapira Y Anaya JM Tincani A Stojanovich L Helicobacter pylori serology in autoimmune diseases—fact or fiction? Clin Chem Lab Med. (2013) 51: 1075– 82. 10.1515/cclm-2012-0477 23079514 · DOI
  74. [76]Sarici SU Gursel O Kurekci E Kesik V Atay A Okutan V. Anticardiolipin antibodies in children with Helicobacter pylori infection. Helicobacter. (2015) 20: 418– 21. 10.1111/hel.12226 25856798 · DOI
  75. [77]Mankaï A Layouni S Ghedira I. Anti Saccharomyces cerevisiae antibodies in patients with anti-β2 glycoprotein I antibodies. J Clin Lab Anal. (2016) 30: 818– 22. 10.1002/jcla.21942 27061484 PMC6806701 · DOI
  76. [78]Sipeki N Davida L Palyu E Altorjay I Harsfalvi J Szalmas PA. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease. World J Gastroenterol. (2015) 21: 6952– 64. 10.3748/wjg.v21.i22.6952 26078573 PMC4462737 · DOI
  77. [79]Mankaï A Sakly W Thabet Y Achour A Manoubi W Ghedira I. Anti-Saccharomyces cerevisiae antibodies in patients with systemic lupus erythematosus. Rheumatol Int. (2013) 33: 665– 9. 10.1007/s00296-012-2431-3 22527140 · DOI
  78. [80]Dai H Li Z Zhang Y Lv P Gao XM. Elevated levels of serum IgA against Saccharomyces cerevisiae mannan in patients with rheumatoid arthritis. Cell Mol Immunol. (2009) 6: 361– 6. 10.1038/cmi.2009.47 19887049 PMC4003219 · DOI
  79. [81]Krause I Blank M Cervera R Font J Matthias T Pfeiffer S. Cross-reactive epitopes on beta2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome. Ann N Y Acad Sci. (2007) 1108: 481– 8. 10.1196/annals.1422.051 17894013 · DOI
  80. [82]Israeli E Grotto I Gilburd B Balicer RD Goldin E Wiik A. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. (2005) 54: 1232– 6. 10.1136/gut.2004.060228 16099791 PMC1774672 · DOI
  81. [83]Amital H Gilburd B Shoenfeld Y. Probiotic supplementation with Lactobacillus casei (Actimel) induces a Th1 response in an animal model of antiphospholipid syndrome. Ann N Y Acad Sci. (2007) 1110: 661– 9. 10.1196/annals.1423.069 17911481 · DOI
  82. [84]Ruff WE Vieira SM Kriegel MA. The role of the gut microbiota in the pathogenesis of antiphospholipid syndrome. Curr Rheumatol Rep. (2015) 17: 472. 10.1007/s11926-014-0472-1 25475595 PMC4394866 · DOI
  83. [86]Furusawa Y Obata Y Fukuda S Endo TA Nakato G Takahashi D Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. (2013) 19: 446– 50. 10.1038/nature12721 24226770 · DOI · Paper page
  84. [88]Kagan VE Tyurina YY Tyurin VA Mohammadyani D Angeli JP Baranov SV. Cardiolipin signaling mechanisms: collapse of asymmetry and oxidation. Antioxid Redox Signal. (2015) 22: 1667– 80. 10.1089/ars.2014.6219 25566681 PMC4486147 · DOI
  85. [89]Lewis RN Mc Elhaney RN. The physicochemical properties of cardiolipin bilayers and cardiolipin-containing lipid membranes. Biochim Biophys Acta. (2009) 1788: 2069– 79. 10.1016/j.bbamem.2009.03.014 19328771 · DOI
  86. [90]Epand RM Epand RF. Lipid domains in bacterial membranes and the action of antimicrobial agents. Biochim Biophys Acta. (2009) 1788: 289– 94. 10.1016/j.bbamem.2008.08.023 18822270 · DOI
  87. [91]Subang R Levine JS Janoff AS Davidson SM Taraschi TF Koike T. Phospholipid-bound beta 2-glycoprotein I induces the production of anti-phospholipid antibodies. J Autoimmun. (2000) 15: 21– 32. 10.1006/jaut.2000.0382 10936025 · DOI
  88. [92]Watanabe T Onda H. Henoch-Schönleinpurpura with antiphospholipid antibodies following an influenza vaccination. Pediatr Nephrol. (2001) 16: 458– 9. 10.1007/s004670100569 11405122 · DOI
  89. [93]Mormile R D'Alterio V Treccagnoli G Sorrentino P. Henoch-Schonleinpurpura with antiphospholipid antibodies after influenza vaccination: how fearful is it in children? Vaccine. (2004) 23: 567– 8. 10.1016/j.vaccine.2004.07.029 15542176 · DOI
  90. [94]Abu-Shakra M Press J Varsano N Levy V Mendelson E Sukenik S. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. (2002) 29: 2555– 7. 12465151
  91. [95]Tarján P Sipka S Lakos G Kiss E Ujj G Szegedi G. Influenza vaccination and the production of anti-phospholipid antibodies in patients with systemic lupus erythematosus. Scand J Rheumatol. (2006) 35: 241– 3. 10.1080/03009740500474552 16766374 · DOI
  92. [96]Toplak N Kveder T Trampuš-Bakija A Subelj V Cučnik S Avčin T. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev. (2008) 8: 134– 8. 10.1016/j.autrev.2008.07.008 18700173 · DOI
  93. [97]Vista ES Crowe SR Thompson LF Air GM Robertson JM Guthridge JM Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus. Lupus. (2012) 21: 168– 74. 10.1177/0961203311429554 22235049 PMC3268677 · DOI
  94. [98]de Medeiros DM Silva CA Bueno C Ribeiro AC Viana Vdos S Carvalho JF. Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production? Lupus. (2014) 23: 1412– 6. 10.1177/0961203314540351 24961747 · DOI
  95. [99]Vainer-Mossel ED Mekori YA Mor A. Ischemic stroke in a patient with lupus following influenza vaccination: a questionable association. Isr Med Assoc J. (2009) 11: 186– 7. 19544712
  96. [100]Korematsu S Miyahara H Kakita A Izumi T. Elevated serum anti-phosphatidylcholineIgG antibodies in patients with influenza vaccination-associated optic neuritis. Vaccine. (2014) 32: 6345– 8. 10.1016/j.vaccine.2014.09.053 25285881 · DOI
  97. [101]Martinuc Porobic J Avcin T Bozic B Kuhar M Cucnik S Zupancic M. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol. (2005) 142: 377– 80. 10.1111/j.1365-2249.2005.02923.x 16232227 PMC1809502 · DOI
  98. [102]Meyer A Rotman-Pikielny P Natour A Levy Y. Antiphospholipid syndrome following a diphtheria-tetanus vaccination: coincidence vs. causality. Isr Med Assoc J. (2010) 12: 638– 9. 21090524
  99. [103]Bizjak M Bruck O Kanduc D Praprotnik S Shoenfeld Y. Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. Semin Hematol. (2016) 53 (Suppl. 1): S48– 50. 10.1053/j.seminhematol.2016.04.014 27312165 · DOI
  100. [104]Dimitrijević L Živković I Stojanović M Petrušić V Živančevi C Simonović S. Vaccine model of antiphospholipid syndrome induced by tetanus vaccine. Lupus. (2012) 21: 195– 202. 10.1177/0961203311429816 22235053 · DOI
  101. [105]Zivkovic I Petrusic V Stojanovic M Inic-Kanada A Stojicevic I Dimitrijevic L. Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant. Innate Immun. (2012) 18: 333– 42. 10.1177/1753425911407361 21926163 · DOI
  102. [106]Blank M Israeli E Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. (2012) 21: 711– 4. 10.1177/0961203312438115 22635209 · DOI
  103. [107]Shoenfeld Y Agmon-Levin N. 'ASIA'—autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. (2011) 36: 4– 8. 10.1016/j.jaut.2010.07.003 20708902 · DOI
  104. [108]Hoffman BJ Sensitivity to sufadiazine resembling acute disseminated lupus erythematosus. Arch Derm Syphilol. (1945) 51: 190– 2. 10.1001/archderm.1945.01510210032007 · DOI
  105. [109]Dlott JS Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep. (2012) 14: 71– 8. 10.1007/s11926-011-0227-1 22160568 · DOI
  106. [110]Canoso RT De Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol. (1988) 27: 272– 5. 10.1002/ajh.2830270408 3128108 · DOI
  107. [111]Triplett DA Brandt JT Musgrave KA Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA. (1988) 259: 550– 4. 10.1001/jama.1988.03720040042024 3121871 · DOI
  108. [112]Kameda H Mimori T Kaburaki J Fujii T Takahashi T Akaishi M. Systemic sclerosis complicated by procainamide-induced lupus and antiphospholipid syndrome. Br J Rheumatol. (1998) 37: 1236– 9. 10.1093/rheumatology/37.11.1236 9851277 · DOI
  109. [113]Gastineau DA Kazmier FJ Nichols WL Bowie EJ. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol. (1985) 19: 265– 75. 10.1002/ajh.2830190308 3925759 · DOI
  110. [114]Walker TS Triplett DA Javed N Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res. (1988) 51: 267– 81. 10.1016/0049-3848(88)90104-1 2972088 · DOI
  111. [115]Bird MR O'Neill AI Buchanan RR Ibrahim KM Des PJ. Lupus anticoagulant in the elderly may be associated with both quinine and quinidine usage. Pathology. (1995) 27: 136– 9. 10.1080/00313029500169742 7567140 · DOI
  112. [116]Rosa-Re D García F Gascon J Angrill J Cervera R. Quinine induced lupus-like syndrome and cardiolipin antibodies. Ann Rheum Dis. (1996) 55: 559– 60. 10.1136/ard.55.8.559-b 8774188 PMC1010240 · DOI
  113. [117]Suwalsky M Sánchez I Bagnara M Sotomayor CP. Interaction of antiarrhythmic drugs with model membranes. Biochim Biophys Acta. (1994) 1195: 189– 96. 10.1016/0005-2736(94)90255-0 7947909 · DOI
  114. [118]Nussio MR Sykes MJ Miners JO Shapter JG. Kinetics membrane disruption due to drug interactions of chlorpromazine hydrochloride. Langmuir. (2009) 25: 1086– 90. 10.1021/la803288s 19093750 · DOI
  115. [119]Lillicrap DP Pinto M Benford K Ford PM Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol. (1990) 93: 771– 5. 10.1093/ajcp/93.6.771 1971739 · DOI
  116. [120]Delluc A Rousseau A Le Galudec M Canceil O Woodhams B Etienne S. Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics. Br J Haematol. (2014) 164: 272– 9. 10.1111/bjh.12627 24383845 · DOI
  117. [121]Aminov RI. Biotic acts of antibiotics. Front Microbiol. (2013) 4: 241. 10.3389/fmicb.2013.00241 23966991 PMC3746177 · DOI
  118. [122]Vyse T So AK. Sulphasalazine induced autoimmune syndrome. Br J Rheumatol. (1992) 31: 115– 6. 10.1093/rheumatology/31.2.115 1346581 · DOI
  119. [123]Graham LE Bell AL. Minocycline-associated lupus-like syndrome with ulnar neuropathy and antiphospholipid antibody. Clin Rheumatol. (2001) 20: 67– 9. 10.1007/s100670170108 11254246 · DOI
  120. [124]Risse J Vieira M Beuret F Petitpain N Zuily S Wahl D. Reversible drug-induced antiphospholipid syndrome. Lupus. (2018) 27: 333– 5. 10.1177/0961203317712463 28592198 · DOI
  121. [125]Gross RL Brucker J Bahce-Altuntas A Abadi MA Lipoff J Kotlyar D. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol. (2011) 30: 1385– 92. 10.1007/s10067-011-1805-3 21706168 · DOI
  122. [126]Magro CM Wang X. Cocaine-associated retiformpurpura: a C5b-9-mediated microangiopathy syndrome associated with enhanced apoptosis and high levels of intercellular adhesion molecule-1 expression. Am J Dermatopathol. (2013) 35: 722– 30. 10.1097/DAD.0b013e31827eaf0b 23392134 · DOI
  123. [127]Souied O Baydoun H Ghandour Z Mobarakai N. Levamisole-contaminated cocaine: an emergent cause of vasculitis and skin necrosis. Case Rep Med. (2014) 2014: 434717. 10.1155/2014/434717 24778656 PMC3977436 · DOI
  124. [128]Lúcio M Lima JL Reis S. Drug-membrane interactions: significance for medicinal chemistry. Curr Med Chem. (2010) 17: 1795– 809. 10.2174/092986710791111233 20345343 · DOI
  125. [129]Calder PC. Feeding the immune system. Proc Nutr Soc. (2013) 72: 299– 309. 10.1017/S0029665113001286 23688939 · DOI · Paper page
  126. [130]Reifen R Blank M Afek A Kopilowiz Y Sklan D Gershwin ME. Dietary polyunsaturated fatty acids decrease anti-dsDNA and anti-cardiolipin antibodies production in idiotype induced mouse model of systemic lupus erythematosus. Lupus. (1998) 7: 192– 7. 10.1191/096120398678919985 9607643 · DOI
  127. [131]Vojdani A. A potential link between environmental triggers and autoimmunity. Autoimmune Dis. (2014) 2014: 437231. 10.1155/2014/437231 24688790 PMC3945069 · DOI
  128. [132]Wolowczuk I Verwaerde C Viltart O Delanoye A Delacre M Pot B. Feeding our immune system: impact on metabolism. Clin Dev Immunol. (2008) 2008: 639803. 10.1155/2008/639803 18350123 PMC2266987 · DOI
  129. [133]Marion-Letellier R Savoye G Ghosh S. Polyunsaturated fatty acids and inflammation. IUBMB Life. (2015) 67: 659– 67. 10.1002/iub.1428 26397837 · DOI
  130. [134]Mizutani H Engelman RW Kinjoh K Kurata Y Ikehara S Matsuzawa Y. Calorie restriction prevents the occlusive coronary vascular disease of autoimmune (NZW x BXSB)F1 mice. Proc Natl Acad Sci USA. (1994) 91: 4402– 6. 10.1073/pnas.91.10.4402 8183920 PMC43793 · DOI
  131. [135]Anderson RM Weindruch R. Metabolic reprogramming, caloric restriction and aging. Trends Endocrinol Metab. (2010) 21: 134– 41. 10.1016/j.tem.2009.11.005 20004110 PMC2831168 · DOI
  132. [136]Riancho-Zarrabeitia L Cubería M Muñoz P López-Hoyos M García-Canale S García-Unzueta M. Vitamin D and antiphospholipid syndrome: a retrospective cohort study and meta-analysis. Semin Arthritis Rheum. (2018) 47: 877– 82. 10.1016/j.semarthrit.2017.10.007 29126718 · DOI
  133. [137]Agmon-Levin N Blank M Zandman-Goddard G Orbach H Meroni PL Tincani A. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. (2011) 70: 145– 50. 10.1136/ard.2010.134817 20980705 · DOI
  134. [138]Gysler SM Mulla MJ Stuhlman M Sfakianaki AK Paidas MJ Stanwood NL. Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast. Am J Reprod Immunol. (2015) 73: 242– 50. 10.1111/aji.12301 25070806 · DOI
  135. [139]Gharavi EE Chaimovich H Cucurull E Celli CM Tang H Wilson WA. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus. (1999) 8: 449– 55. 10.1177/096120339900800607 10483013 · DOI
  136. [140]Blank M Shoenfeld Y Cabilli S Heldman Y Fridkin M Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA. (1999) 96: 5164– 8. 10.1073/pnas.96.9.5164 10220436 PMC21834 · DOI
  137. [141]Blank M Krause I Fridkin M Keller N Kopolovic J Goldberg I. Bacterial induction of autoantibodies to beta2-glycoprotein- I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. (2002) 109: 797– 804. 10.1172/JCI0212337 11901188 PMC150905 · DOI
  138. [142]van Os GM Meijers JC Agar Ç Seron MV Marquart JA Åkesson P. Induction of anti-β2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost. (2011) 9: 2447– 56. 10.1111/j.1538-7836.2011.04532.x 21985124 · DOI
  139. [143]Kuwana M Matsuura E Kobayashi K Okazaki Y Kaburaki J Ikeda Y. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. (2005) 105: 1552– 7. 10.1182/blood-2004-08-3145 15486070 · DOI
  140. [144]Yamaguchi Y Seta N Kaburaki J Kobayashi K Matsuura E Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood. (2007) 110: 4312– 8. 10.1182/blood-2007-07-100008 17726161 · DOI
  141. [145]Ryan BJ Nissim A Winyard PG. Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol. (2014) 2: 715– 24. 10.1016/j.redox.2014.05.004 24955328 PMC4062766 · DOI · Paper page
  142. [146]Matsuura E Lopez LR. Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol. (2004) 11: 103– 11. 10.1080/10446670410001722186 15330445 PMC2270711 · DOI
  143. [147]Giannakopoulos B Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. (2013) 14: 1033– 44. 10.1056/NEJMra1112830 23484830 · DOI
  144. [148]de Laat B van Berkel M Urbanus RT Siregar B de Groot PG Gebbink MF. Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. (2011) 63: 3960– 8. 10.1002/art.30633 21898342 · DOI
  145. [149]Iverson GM Reddel S Victoria EJ Cockerill KA Wang YX Marti-Renom MA Use of single point mutations in domain I of b2-glycoprotein I to determine fine antibody specificity of antiphospholipid autoantibodies. J Immunol. (2002) 169: 7097– 103. 10.4049/jimmunol.169.12.7097 12471146 · DOI
  146. [150]Ioannou Y Pericleous C Giles I Latchman DS Isenberg DA Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. (2007) 56: 280– 90. 10.1002/art.22306 17195232 PMC2117024 · DOI
  147. [151]de Laat B Pengo V Pabinger I Musial J Voskuyl AE Bultink IE. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. (2009) 7: 1767– 73. 10.1111/j.1538-7836.2009.03588.x 19694946 · DOI · Paper page
  148. [152]Pengo V Ruffatti A Tonello M Cuffaro S Banzato A Bison E. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classifypatients at risk. J Thromb Haemost. (2015) 13: 782– 7. 10.1111/jth.12865 25645395 · DOI · Paper page
  149. [153]Iwaniec T Kaczor MP Celinska-Löwenhoff M Polanski S Musiał J Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome. Thromb Res. (2017) 153: 90– 4. 10.1016/j.thromres.2017.02.019 28363116 · DOI
  150. [154]Guo H Zhang Y Li A Wang C Yang S Zhang Y. Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients. Clin Exp Med. (2019). 10.1007/s10238-019-00555-w. [Epub ahead of print]. 31093818 · DOI
  151. [155]Durigutto P Grossi C Borghi MO Macor P Pregnolato F Raschi E. New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica. (2019) 104: 819– 26. 10.3324/haematol.2018.198119 30442725 PMC6442945 · DOI
  152. [156]Andreoli L Fredi M Nalli C Franceschini F Meroni PL Tincani A. Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity. (2013) 46: 302– 6. 10.3109/08916934.2013.783025 23713583 · DOI
  153. [157]Shoenfeld Y Blank M Cervera R Font J Raschi E Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis. (2006) 65: 2– 6. 10.1136/ard.2005.045443 16344491 PMC1797971 · DOI
  154. [158]Hansen KE Kong DF Moore KD Ortel TL. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol. (2001) 28: 2018– 24. 11550969
  155. [159]Girón-González JA García del Río E Rodríguez C Rodríguez-Martorell J Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. (2004) 31: 1560– 7. 15290736
  156. [160]Aslani S Mahmoudi M Karami J Jamshidi AR Malekshahi Z Nicknam MH. Epigenetic alterations underlying autoimmune diseases. Autoimmunity. (2016) 49: 69– 83. 10.3109/08916934.2015.1134511 26761426 · DOI
  157. [161]Schmidl C Delacher M Huehn J Feuerer M. Epigenetic mechanisms regulating T-cell responses. J Allergy Clin Immunol. (2018) 142: 728– 43. 10.1016/j.jaci.2018.07.014 30195378 · DOI
  158. [162]Wu H Deng Y Feng Y Long D Ma K Wang X. Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity. Cell Mol Immunol. (2018) 15: 676– 84. 10.1038/cmi.2017.133 29375128 PMC6123482 · DOI

Cited by

Sorted by citations

Authors
Martirosyan, A., Aminov, R., & Manukyan, G.
Affiliations
  • Russian-Armenian University (AM)
  • University of Aberdeen (GB)
Corresponding author
  • Aminov, Rustam
  • Manukyan, Gayane
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2019-07-10
Volume
10
Pages
1609-1609
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2019.01609
PMC
PMC6635959
OpenAlex
W2957895963
Cited by
62
References
2
Citations by year
2026: 9 · 2025: 3 · 2024: 11 · 2023: 8 · 2022: 10 · 2021: 12 · 2020: 9
FWCI
1.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
Keywords
antiphospholipid antibodies, antiphospholipid syndrome, environmental triggers, autoimmunity, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, lupus anticoagulant, molecular mimicry, infection, autoantibody pathogenesis, prothrombotic activity
MeSH terms
Animals, Autoantibodies, Bacterial Infections, Environment, Environmental Exposure, Humans, Mycoses, Vaccines, Virus Diseases, Autoimmunity, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Microbiota, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review